Vitamin C in Atrial Fibrillation Ablation

• Status: Completed
• Trial end date: 2018-03-13
• Target enrollment: 0
• Participant gender: All

Summary

Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute IV infusion time per dose, compared to matched placebo infusion

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

1. Age >/= 21 years

2. Diagnosis of atrial fibrillation with plans for a catheter-based ablation procedure

3. Ability to provide informed consent and willingness to be included in the study

Exclusion Criteria:

1. Known allergy to Vitamin C

2. Inability to obtain informed consent

3. Diabetes mellitus either requiring the use of insulin therapy or not requiring the use of insulin therapy but which is uncontrolled, defined as a glycosylated hemoglobin of greater than or equal to 8%

4. Prior catheter-based ablation for atrial fibrillation

5. Pregnancy or breast feeding

6. Active renal calculus

7. Active acute or chronic infection (including HIV or hepatitis C)

8. Active or recent (within 5 years) malignancy

9. Autoimmune or autoinflammatory disease

10. Recent or active use of immunosuppressive medications

11. Non-English speaking

12. Ward of the state (inmate, other)